Daxor Corporation Announces That Medical University of South Carolina in Charleston Purchases Blood Volume Analyzer BVA-100

NEW YORK, NY--(Marketwire - December 01, 2009) -

Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced that the Medical University of South Carolina (MUSC) in Charleston has purchased a Blood Volume Analyzer BVA-100® to assist with the diagnosis and treatment of various medical conditions.

Daxor’s Blood Volume Analyzer will be located within the Medical Center’s Nuclear Medicine Department and is already in use by MUSC cardiologist Dr. Adrian Van Bakel and colleagues in a research study to assess whether an indirect measure of blood volume status (intrathoracic impedance, measured by Medtronic’s Optival® system) correlates with direct measurement of blood volume in heart failure patients. Recent published medical reports show that measured blood volume data obtained with the BVA-100 is clinically superior in diagnosing a patient’s volume status to existing surrogate markers, lab tests and physician assessments in heart failure patients.

Other leading medical institutions that have purchased the Blood Volume Analyzer BVA-100 include the Mayo Clinic, the Cleveland Clinic, NYU Medical Center, the National Institutes of Health and Queens Medical Center of Hawaii. Daxor Corporation manufactures and markets the BVA-100, the only FDA approved semi-automated Blood Volume Analyzer, which measures human blood volume. The BVA-100 is used in conjunction with Volumex™, Daxor’s single use diagnostic kit.

Founded in 1824, the Medical University of South Carolina is the oldest medical school in the South. MUSC operates a 750-bed medical center which includes four hospitals. The pediatric cardiology department of the Children’s Hospital was recognized again by U.S. News and World Report as one of America’s Best Children’s Hospitals for cardiology and heart surgery. Their Children’s Heart Center tied three other programs for the lowest mortality rates in the U.S., with a 99% 30-day surgical survival rate. MUSC was also ranked one of America’s Best Hospitals for treatment of digestive disorders, kidney disease, ear, nose and throat disorders, gynecology, respiratory disorders, and rheumatology. In addition, the MUSC Hollings Cancer Center is South Carolina’s only National Cancer Institute-designated center and a national leader in cancer research.

For more information regarding Daxor Corporation’s Blood Volume Analyzer BVA-100, visit Daxor’s website www.Daxor.com, or contact Dr. Sandra Gilbert (Clinical Research Coordinator) at 212-330-8532, sgilbert@daxor.com, Stephen Feldschuh (Chief Operating Officer) at 212-330-8515, stephen@daxor.com or Diane Meegan (Investor Relations) at 212-330-8512, dmeegan@daxor.com.